Treat Rheumatoid Arthritis Early
Studies Show Early, Aggressive Treatment May Lead to Remission
Nov. 13, 2006 (Washington) -- Two studies suggest that treating rheumatoid arthritis (RA) early and aggressively may change its course.
The findings were presented at the 2006 annual meeting of the American College of Rheumatology.
Rheumatoid arthritisis an autoimmune disease caused by the immune system attacking the lining of the joints. It can lead to long-term joint and bone damage and affects 2.1 million Americans, mainly women.
The disease can result in chronic pain, loss of function, and disability, according to the Arthritis Foundation.
There is no cure for the disease. Treatments are aimed at reducing joint inflammation and restoring joint function to near-normal levels.
Early Evidence of Rheumatoid Arthritis
In one study, Dutch researchers studied people with early evidence of rheumatoid arthritis. The researchers show that treating these individuals with the drug methotrexate can possibly prevent the disease from progressing to rheumatoid arthritis.
And in a second study, investigators report that early treatment with methotrexate plus Remicade may result in a drug-free remission in people with rheumatoid arthritis. Remicade is one of a newer category of medications that target specific chemicals that lead to inflammation.
The first study -- called PROMPT -- comprised 110 people with arthritis from an early arthritis clinic in the Netherlands. They received methotrexate or a placebo for one year. Researchers measured joint damage every six months by taking X-rays of the hands and feet -- the joints most commonly affected by rheumatoid arthritis.
People who received methotrexate showed less X-ray damage to the joints after 30 months compared with their counterparts who received a placebo. They were also less likely to develop rheumatoid arthritis, but only if they tested positive for an antibody known as anti-CCP. Anti-CCP antibodies are blood markers that may predict the development of rheumatoid arthritis.